First Horizon Corporation’s Pacira BioSciences PCRX Stock Holding History

First Horizon Corporation’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$0	Hold	3	–	–	﹤0.01%	1174
2021 Q1	$0	Hold	3	–	–	﹤0.01%	1177
2020 Q4	$0	Hold	3	–	–	﹤0.01%	1192
2020 Q3	$0	Buy	+3	New	+$174	﹤0.01%	1139

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

First Horizon Corporation's PCRX Position: Q2 2021 in Review

First Horizon Corporation held its Pacira BioSciences (PCRX) position steady in Q2 2021 at 3 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1174.

First Horizon Corporation first reported a position in PCRX in Q3 2020 and has held it in 4 quarters since. 262 funds tracked by Wall St. Rank hold PCRX as of Q2 2021.

First Horizon Corporation held 3 shares of Pacira BioSciences worth $0 as of Q2 2021.
First Horizon Corporation left its Pacira BioSciences share count unchanged in Q2 2021.
Pacira BioSciences made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2021, its #1174 holding.
First Horizon Corporation first reported a position in Pacira BioSciences in Q3 2020 and has held it in 4 quarters since.
262 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2021.

Based on First Horizon Corporation's 13F filing for Q2 2021, filed 9 Aug 2021.